Low glucose metabolism in hepatocellular carcinoma with GPC3 expression

Table 1 Univariate analysis of the variables related to GPC3 expression in hepatocellular carcinoma n (%)

Variable	GPC3 expression		χ2or t	P value
	Negative	Positive
Gender			1.458	0.227
Male	13 (28.3)	33 (71.7)
Female	5 (55.6)	4 (44.4)
Age (yr)			0.014	0.907
< 50	7 (31.8)	15 (68.2)
≥ 50	11 (33.3)	22 (66.7)
Tumour differentiation			4.341	0.037
Well or moderate	11 (25.0)	33 (75.0)
Poor	7 (63.6)	4 (36.4)
Tumour size (cm)			2.542	0.111
< 5	3 (17.6)	14 (82.4)
≥ 5	15 (39.5)	23 (60.5)
18F-FDG			3.135	0.77
Positive	15 (40.5)	22 (59.5)
Negative	3 (16.7)	15 (83.3)
Intrahepatic lesion number			0.461	0.497
Solitary	11 (29.7)	26 (70.3)
Multiple	7 (38.9)	11 (61.1)
Lymph node metastasis			4.341	0.037
Positive	7 (63.7)	4 (36.4)
Negative	11 (25.0)	33 (75.0)
Distant metastasis			0.836	0.361
Positive	5 (50.0)	5(50.0)
Negative	13 (28.9)	32(71.1)
TNM stage			4.969	0.026
I-II	7 (21.2)	26 (78.8)
III-IV	11 (50.0)	11 (50.0)
Serum AFP (μg/L)			2.645	0.104
< 20	11 (44.0)	14 (56.0)
≥ 20	7 (23.3)	23 (76.7)
HBV infection			0.836	0.361
Positive	13 (28.9)	32 (71.1)
Negative	5 (50.0)	5 (50.0)
Liver cirrhosis			0.445	0.505
Positive	10 (29.4)	24 (70.6)
Negative	8 (38.1)	13 (61.9)
GLUT1			1.863	0.172
High	6 (54.5)	5 (45.5)
Low	12 (27.3)	32 (72.7)
SUVmax	9.56 ± 5.95	6.01 ± 3.55	2.341	0.028
T/N ratio	4.52 ± 2.92	2.62 ± 1.55	2.597	0.017

GPC3: Glypican-3; GLUT1: Glucose transporter 1; SUV: Standard uptake value.